Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aranesp Declines Put More Pressure On Amgen For Denosumab Success

Executive Summary

With sales of Amgen's blockbuster anemia franchise in a freefall and competitive threats to its tumor necrosis factor inhibitor Enbrel looming, the big biotech is banking on the osteoporosis treatment denosumab to drive growth in the years ahead

You may also be interested in...

Amgen Expects Business As Usual For Enbrel

Pfizer set to become Amgen’s partner on Enbrel in North America.

Amgen Submits Denosumab BLA Ahead Of Expectations

Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.

Denosumab Uptake Could Depend On Abating Physicians’ Financial Risk

If denosumab is approved, Amgen may need to provide physicians with a shield against the financial risk of stocking the injectable osteoporosis treatment in their offices

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts